SMT201600264B - POLIMORFI E SOLVATI DI 4-[-2-[[5-METlL-1-(2-NAFTALENlL)-1H-PIRAZOL-3-IL]OSSl]ETlL]MORFOLINA CLORIDRATO - Google Patents
POLIMORFI E SOLVATI DI 4-[-2-[[5-METlL-1-(2-NAFTALENlL)-1H-PIRAZOL-3-IL]OSSl]ETlL]MORFOLINA CLORIDRATOInfo
- Publication number
- SMT201600264B SMT201600264B SM201600264T SM201600264T SMT201600264B SM T201600264 B SMT201600264 B SM T201600264B SM 201600264 T SM201600264 T SM 201600264T SM 201600264 T SM201600264 T SM 201600264T SM T201600264 B SMT201600264 B SM T201600264B
- Authority
- SM
- San Marino
- Prior art keywords
- polymorphoes
- naftalenll
- ossl
- chloridrate
- etll
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382025A EP2361904A1 (en) | 2010-02-04 | 2010-02-04 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof |
| EP10382226A EP2426112A1 (en) | 2010-08-09 | 2010-08-09 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| PCT/EP2011/051630 WO2011095579A1 (en) | 2010-02-04 | 2011-02-04 | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| EP11702056.0A EP2531177B8 (en) | 2010-02-04 | 2011-02-04 | 4-[2-[[5-methyl-1-(2-naphthalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT201600264B true SMT201600264B (it) | 2016-08-31 |
Family
ID=43897079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM201600264T SMT201600264B (it) | 2010-02-04 | 2016-08-04 | POLIMORFI E SOLVATI DI 4-[-2-[[5-METlL-1-(2-NAFTALENlL)-1H-PIRAZOL-3-IL]OSSl]ETlL]MORFOLINA CLORIDRATO |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | USRE47214E1 (it) |
| EP (1) | EP2531177B8 (it) |
| JP (1) | JP5894086B2 (it) |
| KR (2) | KR20120123532A (it) |
| CN (1) | CN102753155B (it) |
| AR (1) | AR080133A1 (it) |
| AU (1) | AU2011212476B2 (it) |
| BR (1) | BR112012018958A8 (it) |
| CA (1) | CA2788024C (it) |
| CO (1) | CO6592093A2 (it) |
| CY (1) | CY1117886T1 (it) |
| DK (1) | DK2531177T3 (it) |
| EC (1) | ECSP12012039A (it) |
| ES (1) | ES2586212T3 (it) |
| HR (1) | HRP20160937T1 (it) |
| HU (1) | HUE029738T2 (it) |
| IL (1) | IL221277A (it) |
| MA (1) | MA34047B1 (it) |
| ME (1) | ME02483B (it) |
| MX (1) | MX339193B (it) |
| NZ (1) | NZ601316A (it) |
| PL (1) | PL2531177T3 (it) |
| PT (1) | PT2531177T (it) |
| RS (1) | RS55046B1 (it) |
| RU (1) | RU2560150C2 (it) |
| SG (2) | SG182628A1 (it) |
| SI (1) | SI2531177T1 (it) |
| SM (1) | SMT201600264B (it) |
| TN (1) | TN2012000347A1 (it) |
| TW (1) | TWI568729B (it) |
| WO (1) | WO2011095579A1 (it) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2116539A1 (en) | 2008-04-25 | 2009-11-11 | Laboratorios Del. Dr. Esteve, S.A. | 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof |
| EP2353591A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| EP2353598A1 (en) | 2010-02-04 | 2011-08-10 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| EP2388005A1 (en) | 2010-05-21 | 2011-11-23 | Laboratorios Del. Dr. Esteve, S.A. | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy |
| TWI522361B (zh) | 2010-07-09 | 2016-02-21 | 艾伯維公司 | 作為s1p調節劑的稠合雜環衍生物 |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| TW201206893A (en) | 2010-07-09 | 2012-02-16 | Abbott Healthcare Products Bv | Bisaryl (thio) morpholine derivatives as S1P modulators |
| EP2415471A1 (en) | 2010-08-03 | 2012-02-08 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in opioid-induced hyperalgesia |
| EP2426111A1 (en) * | 2010-08-09 | 2012-03-07 | Laboratorios Del. Dr. Esteve, S.A. | 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms |
| EP2524694A1 (en) | 2011-05-19 | 2012-11-21 | Laboratorios Del. Dr. Esteve, S.A. | Use of sigma ligands in diabetes type-2 associated pain |
| EP2792352A1 (en) | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
| SG11201604480PA (en) | 2013-12-17 | 2016-07-28 | Esteve Labor Dr | SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS |
| US20160310501A1 (en) | 2013-12-17 | 2016-10-27 | Laboratorios Del Dr. Esteve, S.A. | Gabapentinoids and sigma receptor ligands combinations |
| AR108682A1 (es) | 2016-06-06 | 2018-09-12 | Esteve Labor Dr | Derivados de pirazol-3-iloxi ligandos del receptor sigma |
| TW201806601A (zh) | 2016-07-12 | 2018-03-01 | 以斯提夫博士實驗室股份有限公司 | σ受體配體在皰疹後遺疼痛中的用途 |
| WO2018059420A1 (zh) * | 2016-09-27 | 2018-04-05 | 苏州科睿思制药有限公司 | E52862盐酸盐晶型h及其制备方法 |
| WO2019068771A1 (en) | 2017-10-04 | 2019-04-11 | Esteve Pharmaceuticals, S.A. | USE OF SIGMA RECEPTOR LIGANDS AGAINST AGE-RELATED COGNITIVE DISORDERS |
| BR112022008113A2 (pt) | 2019-10-31 | 2022-07-19 | Escape Bio Inc | Formas sólidas de um modulador de receptor s1p |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
| EP2325174A1 (en) * | 2004-08-27 | 2011-05-25 | Laboratorios Del. Dr. Esteve, S.A. | Sigma receptor inhibitors |
| WO2007098953A1 (en) * | 2006-03-01 | 2007-09-07 | Laboratorios Del Dr. Esteve, S.A. | Pyrazole derivatives as sigma receptor inhibitors |
| US7695199B2 (en) | 2006-07-20 | 2010-04-13 | Finisar Corporation | Optical subassembly having insertable cylindrical sleeve |
| CN101328155B (zh) * | 2007-06-20 | 2010-11-03 | 上海医药工业研究院 | 噁唑烷衍生物及其制备方法和应用 |
| EP2113501A1 (en) * | 2008-04-25 | 2009-11-04 | Laboratorios Del. Dr. Esteve, S.A. | 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors |
-
2011
- 2011-02-04 KR KR1020127023081A patent/KR20120123532A/ko active Search and Examination
- 2011-02-04 US US15/616,347 patent/USRE47214E1/en active Active
- 2011-02-04 CN CN201180008354.5A patent/CN102753155B/zh active Active
- 2011-02-04 ME MEP-2016-154A patent/ME02483B/me unknown
- 2011-02-04 ES ES11702056.0T patent/ES2586212T3/es active Active
- 2011-02-04 EP EP11702056.0A patent/EP2531177B8/en active Active
- 2011-02-04 HU HUE11702056A patent/HUE029738T2/en unknown
- 2011-02-04 DK DK11702056.0T patent/DK2531177T3/en active
- 2011-02-04 CA CA2788024A patent/CA2788024C/en not_active Expired - Fee Related
- 2011-02-04 SG SG2012053724A patent/SG182628A1/en unknown
- 2011-02-04 MA MA35183A patent/MA34047B1/fr unknown
- 2011-02-04 BR BR112012018958A patent/BR112012018958A8/pt not_active Application Discontinuation
- 2011-02-04 KR KR1020187015725A patent/KR20180063379A/ko not_active Application Discontinuation
- 2011-02-04 US US13/577,078 patent/US9051275B2/en not_active Ceased
- 2011-02-04 PL PL11702056.0T patent/PL2531177T3/pl unknown
- 2011-02-04 AR ARP110100380A patent/AR080133A1/es unknown
- 2011-02-04 RU RU2012137495/04A patent/RU2560150C2/ru not_active IP Right Cessation
- 2011-02-04 JP JP2012551631A patent/JP5894086B2/ja active Active
- 2011-02-04 RS RS20160612A patent/RS55046B1/sr unknown
- 2011-02-04 MX MX2012009018A patent/MX339193B/es active IP Right Grant
- 2011-02-04 PT PT117020560T patent/PT2531177T/pt unknown
- 2011-02-04 NZ NZ601316A patent/NZ601316A/en not_active IP Right Cessation
- 2011-02-04 SG SG10201500832PA patent/SG10201500832PA/en unknown
- 2011-02-04 WO PCT/EP2011/051630 patent/WO2011095579A1/en active Application Filing
- 2011-02-04 AU AU2011212476A patent/AU2011212476B2/en not_active Ceased
- 2011-02-04 SI SI201130895A patent/SI2531177T1/sl unknown
- 2011-02-08 TW TW100104115A patent/TWI568729B/zh not_active IP Right Cessation
-
2012
- 2012-07-04 TN TNP2012000347A patent/TN2012000347A1/en unknown
- 2012-07-13 EC ECSP12012039 patent/ECSP12012039A/es unknown
- 2012-08-02 IL IL221277A patent/IL221277A/en not_active IP Right Cessation
- 2012-09-04 CO CO12151303A patent/CO6592093A2/es not_active Application Discontinuation
-
2016
- 2016-07-25 HR HRP20160937TT patent/HRP20160937T1/hr unknown
- 2016-08-04 SM SM201600264T patent/SMT201600264B/it unknown
- 2016-08-08 CY CY20161100779T patent/CY1117886T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT201600264B (it) | POLIMORFI E SOLVATI DI 4-[-2-[[5-METlL-1-(2-NAFTALENlL)-1H-PIRAZOL-3-IL]OSSl]ETlL]MORFOLINA CLORIDRATO | |
| SMT201600021B (it) | Nuovi composti di chinolina sostituiti come inibitori della s-nitrosoglutatione reduttasi | |
| SMT201600135B (it) | Nuovi inibitori della s-nitrosoglutatione riduttasi | |
| BR112013025353A2 (pt) | combinações de compostos de inibidores de akt e erlotinibe e métodos de uso | |
| HK1191000A1 (en) | Macrocyclic inhibitors of flaviviridae viruses | |
| DK2526254T3 (da) | Wellbore knock-out chamber and related methods of use | |
| BRPI1012333A2 (pt) | atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso | |
| BR112013014119A2 (pt) | novos moduladores e métodos de uso | |
| BR112013014231A2 (pt) | composição de higiene pessoal e uso da composição de higiene pessoal | |
| EP2603201A4 (en) | LIPOSOME COMPOSITIONS AND USE METHOD THEREFOR | |
| BR112013010988A2 (pt) | composição fluída e uso | |
| ZA201208770B (en) | New forms of rifaximin and uses thereof | |
| BR112013006016A2 (pt) | compostos de azabenzotiazol, composições e métodos de uso | |
| SMT201700064B (it) | Antagonisti di d2, metodi di sintesi e metodi di uso | |
| BRPI1014544A2 (pt) | anticorpors anti-il-17f e metodos de uso dos mesmos | |
| BR112014006291A2 (pt) | composição e utilização da composição | |
| FI20095529A0 (fi) | Probioottien uusi käyttö | |
| ZA201301795B (en) | Inhibitors of notum pectinacetylesterase and methods of their use | |
| BR112013010331A2 (pt) | composições adesivas crepadas e métodos de uso dessas composições | |
| IT1403845B1 (it) | Sonda di tastaggio e relativo metodo di controllo | |
| BR112012024642A2 (pt) | produto de aço e uso de um produto de aço | |
| DE11786796T8 (de) | Antigenpeptid und verwendung davon | |
| BR112014013746A2 (pt) | aparelho de descarga e uso do aparelho de descarga | |
| IT1402715B1 (it) | Sonda di tastaggio | |
| BR112013013551A2 (pt) | composto e uso médico do mesmo |